Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada

Stroke

Volumn 38, Issue 6, 2007, Pages 1952-1955

  Yip, Todd R ^a   Demaerschalk, Bart M ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Acute ischemic; Costs; Economics; Medical; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CANADA; CEREBROVASCULAR ACCIDENT; COST CONTROL; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ACUTE DISEASE; BRAIN ISCHEMIA; CANADA; CEREBROVASCULAR ACCIDENT; COST SAVINGS; HUMANS; INFUSIONS, INTRAVENOUS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34249779838     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.479477     Document Type: Article

References (26)

1. Heart and Stroke Foundation. c2006 [cited 2006 May 24]. Available at: http://ww2.heartandstroke.ca/Page.asp?PageID=33&ArticleID=428&Src= stroke&From=SubCategory.
2. Hill MD, Buchan AM. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:1307-1312.
3. Campbell C. A stroke strategy for Canada. Canadian Stroke Network. [cited 2005 July 9]. Available at: http://canadianstrokenetwork.ca/news/ newsletters/newsletter8en.pdf.
4. Demaerschalk BM, Silver B, Merino JG, Wong E, Hill MD, Poncha F, Foell B, Tamayo A, Buchan A, Hachinski V. Cost utility analysis of intravenous tissue plasminogen activator in acute stroke in Canada [abstract]. Stroke. 2003;34:248-249.
5. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD, NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50:883-890.
6. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, Marra CA. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 2001;19:927-936.
7. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35:14907. Epub 2004 Apr 22.
8. International classification of diseases, ninth revision, clinical modification (ICD-9-CM). [cited 2006 Jun 26]. Hyattsville, MD: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics.
9. Bank of Canada. [cited 2006 Jun 26]. Available at: http://www. bankofcanada.ca/en/rates/inflation_calc.html.
10. U.S. Consumer Price Index inflation calculator. [cited 2006 Jun 26]. Available from: http://data.bls.gov/cgi-bin/cpicalc.pl.
11. Mamdani MM, Tu JV. Emergency/Acute Stroke Task Group Economic Decision Analysis Model. Appendix 5. Ontario Ministry of Health and Long-Term Care. Report of the Joint Stroke Strategy Working Group, June 2000. c2002 [cited 2006 Jun 26]. Available at: http://www.health.gov.on.ca/english/public/pub/ ministry_reports/stroke/stroke_mn.html.
12. Teng J, Mayo NE, Latimer E, Hanley J, Wood-Dauphinee S, Cote R, Scott S. Costs and caregiver consequences of early supported discharge for stroke patients. Stroke. 2003;34:528-536.
13. Demaerschalk BM, Yip TR. Economic benefit of increasing utilizaton of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500-2503. Epub 2005 Oct 13.
14. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States [letter]. Stroke. 2006;37:943-944.
15. Foley NC, Teasell RW, Bhogal SK, Salter KL. The rehabilitation outcomes of stroke patients receiving Recombinant Tissue Plasminogen Activator (rt-PA) [abstract]. Stroke. 2004;35:e311.
16. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 2005;65:1169-1174.
17. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). Stroke. 2005;36:1512-1518. Epub 2005 Jun 16.
18. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
19. Weir NU, Buchan AM. A study of the workload and effectiveness of a comprehensive acute stroke service. J Neurol Neurosurg Psychiatry. 2005;76:863-865.
20. Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR. Time of hospital presentation in patients with acute stroke. Arch Intern Med. 1993;153:2558-2561.
21. Canada Institute for Health Information. Heart disease and stroke. [cited 2006 May 24]. Available at: http://secure.cihi.ca/cihiweb/dispPage.jsp? cw_page=statistics_topic_e.
22. Canadian Stroke Network. Billions of dollars, tens of thousands of lives at stake: why aren't proven stroke solutions being used consistently in Canada? [updated 2006 Jun 14; cited 2006 Jul 6]. Available at: http://www. canadianstrokenetwork.ca/media/releases/release.june152006.en.pdf.
23. Kapral MK, Laupacis A, Phillips SJ, Silver FL, Hill MD, Fang J, Richards J, Tu JV. Investigators of the Registry of the Canadian Stroke Network. Stroke care delivery in institutions participating in the Registry of the Canadian Stroke Network. Stroke. 2004;35:1756-1762 Epub 2004 May 13.
24. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing. 2004;33:116-121.
25. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM. 2004;97:273-279.
26. Lindsay MP, Kapral MK, Gladstone D, Holloway R, Tu JV, Laupacis A, Grimshaw JM. The Canadian Stroke Quality of Care Study: establishing indicators for optimal acute stroke care. CMAJ. 2005;172:363-365.